Strategy Asset Managers LLC boosted its position in Pfizer Inc. (NYSE: PFE – Get Rating) by 2.8% during the 1st quarter, Holdings Channel.com reports. The firm owned 201,408 shares of the biopharmaceutical company stock after purchasing an additional 5,536 shares during the period. Pfizer comprises about 2.3% of Strategy Asset Managers LLC’s portfolio, making the stock its 9th biggest holding. Strategy Asset Managers LLC’s holdings in Pfizer were worth $ 10,427,000 at the end of the most recent quarter.
A number of other institutional investors have also recently bought and sold shares of the stock. Bank OZK raised its position in shares of Pfizer by 0.3% in the fourth quarter. Bank OZK now owns 68,883 shares of the biopharmaceutical company stock worth $ 4,067,000 after buying an additional 195 shares in the last quarter. TimeScale Financial Inc. raised its position in shares of Pfizer by 2.9% in the fourth quarter. TimeScale Financial Inc. now owns 6,978 shares of the biopharmaceutical company stock worth $ 412,000 after buying an additional 196 shares in the last quarter. Bath Savings Trust Co raised its position in shares of Pfizer by 0.5% in the fourth quarter. Bath Savings Trust Co now owns 39,684 shares of the biopharmaceutical company stock worth $ 2,344,000 after buying an additional 200 shares in the last quarter. Fruth Investment Management increased its stake in Pfizer by 0.7% in the fourth quarter. Fruth Investment Management now owns 29,313 shares of the biopharmaceutical company stock valued at $ 1,730,000 after acquiring an additional 200 shares during the last quarter. Finally, Winfield Associates Inc. increased its stake in Pfizer by 0.9% in the fourth quarter. Winfield Associates Inc. now owns 21,557 shares of the biopharmaceutical company stock valued at $ 1,273,000 after acquiring an additional 200 shares during the last quarter. Institutional investors and hedge funds own 66.50% of the company stock.
A number of research analysts recently commented on the company. Barclays set a $ 52.00 target price on Pfizer in a research note on Tuesday, May 17th. The Goldman Sachs Group set a $ 51.00 target price on Pfizer in a research note on Wednesday, May 25th. Wells Fargo & Company reduced their target price on Pfizer from $ 60.00 to $ 55.00 in a research note on Wednesday, May 4th. Berenberg Bank set a $ 50.00 target price on Pfizer in a research note on Friday, May 27th. Finally, Morgan Stanley started coverage on Pfizer in a research note on Wednesday, April 6th. They set an “equal weight” rating and a $ 55.00 price objective on the stock. Nine investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $ 57.26.
Pfizer stock opened at $ 48.11 on Wednesday. The company has a current ratio of 1.39, a quick ratio of 1.13 and a debt-to-equity ratio of 0.43. The firm has a 50-day moving average of $ 50.65 and a 200-day moving average of $ 52.24. The firm has a market cap of $ 269.94 billion, a P / E ratio of 11.03, a P / E / G ratio of 0.56 and a beta of 0.76. Pfizer Inc. has a 1-year low of $ 38.82 and a 1-year high of $ 61.71.
Pfizer (NYSE: PFE – Get Rating) last issued its quarterly earnings data on Tuesday, May 3rd. The biopharmaceutical company reported $ 1.62 EPS for the quarter, missing the consensus estimate of $ 1.66 by ($ 0.04). Pfizer had a return on equity of 38.29% and a net margin of 26.97%. The company had revenue of $ 25.66 billion during the quarter, compared to analysts’ expectations of $ 24.73 billion. During the same quarter last year, the business earned $ 0.93 earnings per share. The business’s quarterly revenue was up 76.8% on a year-over-year basis. Research analysts forecast that Pfizer Inc. will post 6.61 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which was paid on Friday, June 10th. Shareholders of record on Friday, May 13th were issued a $ 0.40 dividend. The ex-dividend date of this dividend was Thursday, May 12th. This represents a $ 1.60 annualized dividend and a yield of 3.33%. Pfizer’s dividend payout ratio (DPR) is presently 36.70%.
In other news, SVP Jennifer B. Damico sold 4,000 shares of Pfizer stock in a transaction that occurred on Monday, May 16th. The shares were sold at an average price of $ 50.50, for a total transaction of $ 202,000.00. Following the completion of the transaction, the senior vice president now directly owns 15,064 shares in the company, valued at $ 760,732. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP William R. Carapezzi, Jr. sold 32,908 shares of Pfizer stock in a transaction that occurred on Thursday, May 12th. The shares were sold at an average price of $ 50.00, for a total transaction of $ 1,645,400.00. Following the transaction, the executive vice president now owns 38,146 shares of the company stock, valued at $ 1,907,300. The disclosure for this sale can be found here. Insiders sold 41,126 shares of company stock valued at $ 2,075,003 over the last 90 days. 0.05% of the stock is currently owned by company insiders.
Pfizer Company Profile: (Get Rating)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women’s health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE: PFE – Get Rating).
Receive News & Ratings for Pfizer Daily: – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Pfizer and related companies with MarketBeat.com’s FREE daily email newsletter.